Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI response text consists of label-claim mappings that appear fully supported by the supplied ONGLYZA FDA label excerpts (indication, dosing, pancreatitis, hypersensitivity/contraindication, hypoglycemia risk with sulfonylurea/insulin, renal impairment dosing and hemodialysis timing, QTc statement, and macrovascular outcomes). No direct contradictions were identified. Some potential safety areas (boxed warnings, pregnancy, and pediatric) were not assessable because corresponding label text was not included.
Category Scores
Accurate Statements
ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.
1 INDICATIONS AND USAGE: “ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.”
ONGLYZA should not be used for type 1 diabetes mellitus or diabetic ketoacidosis.
1 INDICATIONS AND USAGE: “ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis…”
Postmarketing reports of acute pancreatitis; observe carefully; discontinue promptly if suspected; pancreatitis history risk is unknown.
5 WARNINGS AND PRECAUTIONS (5.1): “There have been postmarketing reports of acute pancreatitis…” plus “After initiation… observed carefully… If pancreatitis is suspected, ONGLYZA should promptly be discontinued…” and “It is unknown whether patients with a history of pancreatitis are at an increased risk…”
When used with a sulfonylurea or insulin, incidence of confirmed hypoglycemia is increased; a lower dose of insulin/secretagogue may be required to minimize risk.
5 WARNINGS AND PRECAUTIONS (5.2): “incidence of confirmed hypoglycemia was increased…” and “Therefore, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia.”
Serious hypersensitivity reactions can occur (e.g., anaphylaxis, angioedema, exfoliative skin conditions) and if suspected, discontinue and assess for other causes; history of serious hypersensitivity is a contraindication.
5 WARNINGS AND PRECAUTIONS (5.3): “There have been postmarketing reports of serious hypersensitivity reactions… include anaphylaxis, angioedema, and exfoliative skin conditions.” plus “If a serious hypersensitivity reaction is suspected, discontinue…”; and 4 CONTRAINDICATIONS: “History of a serious hypersensitivity reaction…”
Renal impairment dosing: no adjustment for mild renal impairment; 2.5 mg once daily for moderate/severe renal impairment or ESRD on hemodialysis; administer after hemodialysis; periodic renal assessment recommended prior to and thereafter.
2.2: “No dosage adjustment… mild…”; “The dose… is 2.5 mg once daily for patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD) requiring hemodialysis…”; “ONGLYZA should be administered following hemodialysis.”; and “assessment of renal function is recommended prior to initiation… and periodically thereafter.”
QTc: ONGLYZA not associated with clinically meaningful QTc prolongation or heart rate prolongation at daily doses up to 40 mg.
7 DRUG INTERACTIONS (QTc statement): “ONGLYZA was not associated with clinically meaningful prolongation of the QTc interval or heart rate…”
Macrovascular outcomes: no conclusive evidence of macrovascular risk reduction established.
5 WARNINGS AND PRECAUTIONS (5.4): “There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction…”
Unsupported Statements
Contradictions
Important Omissions
The AI response declares a boxed-warning check as “present: false,” but no boxed-warning text/excerpt was provided in the supplied label excerpts to confirm whether a boxed warning exists for ONGLYZA.
Importance:
Moderate
Potential safety compliance for pregnancy and pediatric populations could not be audited because the AI response notes pregnancy/pediatric sections were not included; thus it does not evaluate whether any required label statements for those populations were accurately represented.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI response’s evaluated label mappings are largely supported by the provided excerpts with no contradictions; however, boxed-warning status and pregnancy/pediatric labeling were not assessable from the excerpt set, creating limited audit uncertainty rather than direct label conflict.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Boxed warning presence cannot be confirmed from provided excerpts; pregnancy and pediatric label compliance were not auditable.
Suggested Improvement
Limit conclusions about boxed warnings and any pregnancy/pediatric claims unless the relevant FDA label sections are included in the supplied excerpts.